基于通降法的中药联合质子泵抑制剂(PPI)降阶梯治疗非糜烂性反流病:多中心随机对照临床试验研究方案
针对单独使用PPI应答不佳的非糜烂性反流病患者,设计多中心双盲随机对照试验,纳入174例受试者,随机分为中药颗粒联合PPI降阶梯组(n=87)与中药颗粒安慰剂联合PPI降阶梯组(n=87),疗程6周、随访4周,主要结局为烧心和反流的视觉模拟量表评分及主要症状量表,旨在评估中药联合PPI降阶梯的疗效及减少PPI依赖的可行性。
要点
- 单独使用PPI治疗的非糜烂性反流病患者中,近50%应答不佳。
- 该试验为多中心、双盲、随机对照试验,计划招募174例受试者,两组各87例。
- 两组均接受6周治疗和4周随访,主要结局包括烧心和反流的视觉模拟量表评分及主要症状量表。
核心结论
- 该试验旨在评估基于通降法的中药颗粒联合PPI降阶梯治疗对PPI单独应答不佳的非糜烂性反流病患者的疗效,并探索补充中药颗粒后能否减少PPI剂量,为减少或撤除PPI依赖提供可行方案。
研究设计与样本
- 多中心、双盲、随机对照试验,设两个平行组,计划招募174例受试者。
- 受试者随机分为中药颗粒联合PPI降阶梯组(n=87)和中药颗粒安慰剂联合PPI降阶梯组(n=87)。
- 两组均接受6周治疗和4周随访,每次访视评估相关症状、心理健康状态和生活质量。
主要发现
- 该文为研究方案,未报告试验结果。
关键数值与推荐
- 主要结局指标包括烧心和反流的视觉模拟量表(VAS)评分及主要症状量表。
- 次要结局指标包括PPI撤药率、症状复发率、次要症状量表、SF-36、PRO、SAS、SDS、GERD-HRQL及中医证候量表。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Non-erosive reflux disease (NERD) is characterized by typical gastroesophageal reflux symptoms, such as heartburn and regurgitation but an absence of esophageal mucosal damage during upper gastrointestinal endoscopy. Although proton pump inhibitors (PPIs) are the first line therapy, almost 50% of patients with NERD fail to respond to this treatment. Traditional Chinese medicine (TCM) can better relieve the symptoms of NERD. Therefore, a randomized controlled trial (RCT) was designed to investigate the efficiency of TCM granules based on Tongjiang (TJ) methodology combined with PPI step-down therapy for NERD patients who did not respond to PPIs alone. METHOD: This multicentered, double-blinded, RCT with two parallel groups will recruit 174 participants who will be randomized into the TCM granules combined with PPI step-down group (n = 87) and the TCM granules placebo combined with PPI step-down group (n = 87). Both groups of participants will receive 6 weeks of treatment and 4 weeks of follow-up, and all participants will be assessed for related symptoms, mental health status, and quality of life at each visit. The primary outcome measurements include visual analog scale (VAS) for heartburn and regurgitation and the major symptoms scale. The secondary outcome measurements include PPI withdrawal rate, symptom recurrence rate, minor symptoms scale, SF-36, PRO, SAS, SDS, GERD-HRQL, and TCM syndromes scales. DISCUSSION: Previous research has shown that TCM is capable to alleviate NERD symptoms. This trial will help to provide a better understanding of the synergistic efficiency of the combination of TCM and PPIs, to explore whether the dosage of PPIs can be reduced after the supplement of TCM granules and to provide a feasible plan to reduce dependencies or withdraw NERD patients from PPIs. The outcome of this trial is expected to reduce the symptom recurrence rates, lessen patients' physical and psychological burdens, and achieve good social benefits. TRIAL REGISTRATION: Clinicaltrials.gov NCT04340297. Registered on April 9, 2020.
引用
- Li X, Wu H, Zhang B, et al. Traditional Chinese medicine based on Tongjiang methodology combined with proton pump inhibitor (PPI) step-down in treating non-erosive reflux disease: a study protocol for a multicentered, randomized controlled clinical trial. Trials. 2022. PMID: 36258217. doi:10.1186/s13063-022-06811-x
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。